标题
Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer
作者
关键词
-
出版物
Biomedicines
Volume 10, Issue 11, Pages 2775
出版商
MDPI AG
发表日期
2022-11-02
DOI
10.3390/biomedicines10112775
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
- (2022) C.E. Geyer et al. ANNALS OF ONCOLOGY
- A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.
- (2022) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Hallmarks of DNA replication stress
- (2022) Sneha Saxena et al. MOLECULAR CELL
- TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stress
- (2022) Hiroyuki Ueno et al. Communications Biology
- Recent advances in therapeutic strategies for triple-negative breast cancer
- (2022) Yun Li et al. Journal of Hematology & Oncology
- DNA-PKcs promotes fork reversal and chemoresistance
- (2022) Diego Dibitetto et al. MOLECULAR CELL
- An Overview of PARP Inhibitors for the Treatment of Breast Cancer
- (2021) Laura Cortesi et al. Targeted Oncology
- Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
- (2021) Mark R. Middleton et al. BRITISH JOURNAL OF CANCER
- Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.
- (2021) Ashley P Wright et al. JOURNAL OF CLINICAL ONCOLOGY
- Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
- (2021) Ke Cong et al. MOLECULAR CELL
- Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
- (2021) Ukhyun Jo et al. Cancers
- Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression
- (2021) Martina Proctor et al. Cancers
- Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
- (2021) Karama Asleh et al. npj Breast Cancer
- Replication stress: from chromatin to immunity and beyond
- (2021) Yea-Lih Lin et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
- (2021) Anne Roulston et al. MOLECULAR CANCER THERAPEUTICS
- Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers
- (2021) Daniel J. McGrail et al. Science Translational Medicine
- Human DNA-PK activates a STING-independent DNA sensing pathway
- (2020) Katelyn Burleigh et al. Science Immunology
- Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases
- (2020) Alexandra S Zimmer et al. Future Oncology
- Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
- (2020) Todd M. Pitts et al. Cancers
- The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
- (2020) Matteo Berti et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib ( LY2606368 ) in BRCA Wild‐Type , Advanced Triple‐Negative Breast Cancer
- (2020) Margaret E. Gatti‐Mays et al. ONCOLOGIST
- Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene
- (2020) Christopher Butler et al. Translational Oncology
- Topoisomerase 1 prevents replication stress at R-loop-enriched transcription termination sites
- (2020) Alexy Promonet et al. Nature Communications
- Role of DNA repair defects in predicting immunotherapy response
- (2020) Jing Zhang et al. Biomarker Research
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
- (2020) Mark T. J. van Bussel et al. BRITISH JOURNAL OF CANCER
- Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. CLINICAL CANCER RESEARCH
- Exploiting DNA Replication Stress for Cancer Treatment
- (2019) Tajinder Ubhi et al. CANCER RESEARCH
- EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy
- (2019) Julian Puppe et al. CLINICAL CANCER RESEARCH
- Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.
- (2019) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.
- (2019) Manish R. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Replication-Coupled DNA Repair
- (2019) David Cortez MOLECULAR CELL
- Defining and Modulating ‘BRCAness’
- (2019) Andrea K. Byrum et al. TRENDS IN CELL BIOLOGY
- Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically.
- (2019) Lucy C. Riches et al. MOLECULAR CANCER THERAPEUTICS
- Replication Stress Response Links RAD52 to Protecting Common Fragile Sites
- (2019) Xiaohua Wu Cancers
- Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer
- (2019) Nazareth et al. Cancers
- The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models
- (2019) Antje M. Wengner et al. MOLECULAR CANCER THERAPEUTICS
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis
- (2019) Marianne Samir Makboul Issac et al. NEOPLASIA
- RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
- (2019) Toma et al. Cancers
- WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
- (2019) Andrea Sand et al. CANCER LETTERS
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
- (2018) A Italiano et al. ANNALS OF ONCOLOGY
- Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers
- (2018) N J Birkbak et al. ANNALS OF ONCOLOGY
- Abstract P6-06-04: Targeting replication stress in triple negative breast cancer treatment regimen: An emerging approach
- (2018) S Rajamanickam et al. CANCER RESEARCH
- Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germlineBRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)
- (2018) SM Domchek et al. CANCER RESEARCH
- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- (2018) Hana Hanzlikova et al. MOLECULAR CELL
- PIDD mediates the association of DNA-PKcs and ATR at stalled replication forks to facilitate the ATR signaling pathway
- (2018) Yu-Fen Lin et al. NUCLEIC ACIDS RESEARCH
- Targeting the replication stress response in cancer
- (2018) Josep V. Forment et al. PHARMACOLOGY & THERAPEUTICS
- Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
- (2018) Jone Michelena et al. Nature Communications
- Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype
- (2018) Daniel J. McGrail et al. Cell Reports
- Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
- (2018) Julie M. Diamond et al. Cancer Immunology Research
- Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
- (2018) Juan Jin et al. NEOPLASIA
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
- (2018) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- SAMHD1 acts at stalled replication forks to prevent interferon induction
- (2018) Flavie Coquel et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties
- (2018) Bhanvi Mishra et al. CANCER BIOLOGY & THERAPY
- A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1
- (2017) Erkin Erdal et al. GENES & DEVELOPMENT
- Replication Fork Reversal: Players and Guardians
- (2017) Annabel Quinet et al. MOLECULAR CELL
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51 Nucleofilaments
- (2017) Arun Mouli Kolinjivadi et al. MOLECULAR CELL
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- The impact of replication stress on replication dynamics and DNA damage in vertebrate cells
- (2017) Hervé Técher et al. NATURE REVIEWS GENETICS
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- Replication fork reversal triggers fork degradation in BRCA2-defective cells
- (2017) Sofija Mijic et al. Nature Communications
- The prognostic significance of Cdc6 and Cdt1 in breast cancer
- (2017) Ravikiran Mahadevappa et al. Scientific Reports
- Inhibition of DNA2 nuclease as a therapeutic strategy targeting replication stress in cancer cells
- (2017) S Kumar et al. Oncogenesis
- Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer
- (2016) Miroslava Juríková et al. ACTA HISTOCHEMICA
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- The antitumor toxin CD437 is a direct inhibitor of DNA polymerase α
- (2016) Ting Han et al. Nature Chemical Biology
- Replication stress: getting back on track
- (2016) Matteo Berti et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
- (2016) Fei Huang et al. NUCLEIC ACIDS RESEARCH
- Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
- (2016) Xia Ding et al. Nature Communications
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- (2016) Chris T. Williamson et al. Nature Communications
- Replication stress: getting back on track
- (2016) Matteo Berti et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to Chemotherapy
- (2016) Wenpeng Liu et al. EBioMedicine
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- (2015) Leisha A. Emens et al. CANCER RESEARCH
- DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair
- (2015) S. Ying et al. CANCER RESEARCH
- Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation
- (2015) RICHARD PONCE-CUSI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- DNA2 drives processing and restart of reversed replication forks in human cells
- (2015) Saravanabhavan Thangavel et al. JOURNAL OF CELL BIOLOGY
- Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
- (2015) Ralph Zellweger et al. JOURNAL OF CELL BIOLOGY
- Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways
- (2015) M. Aarts et al. MOLECULAR CANCER THERAPEUTICS
- ATR-Mediated Phosphorylation of FANCI Regulates Dormant Origin Firing in Response to Replication Stress
- (2015) Yu-Hung Chen et al. MOLECULAR CELL
- Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
- (2015) Rémi Buisson et al. MOLECULAR CELL
- TIPIN depletion leads to apoptosis in breast cancer cells
- (2015) Céline Baldeyron et al. Molecular Oncology
- Exploiting replicative stress to treat cancer
- (2015) Matthias Dobbelstein et al. NATURE REVIEWS DRUG DISCOVERY
- DNA replication origin activation in space and time
- (2015) Michalis Fragkos et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors
- (2015) Shinya Abe et al. Oncotarget
- Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
- (2014) J. Balmaña et al. ANNALS OF ONCOLOGY
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- DNA-PK phosphorylation of RPA32 Ser4/Ser8 regulates replication stress checkpoint activation, fork restart, homologous recombination and mitotic catastrophe
- (2014) Amanda K. Ashley et al. DNA REPAIR
- ATR inhibition preferentially targets homologous recombination-deficient tumor cells
- (2014) M Krajewska et al. ONCOGENE
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- Replication Stress and Chromatin Context Link ATM Activation to a Role in DNA Replication
- (2013) Monica M. Olcina et al. MOLECULAR CELL
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
- (2012) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Homologous recombination and its regulation
- (2012) L. Krejci et al. NUCLEIC ACIDS RESEARCH
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- An Oncogene-Induced DNA Damage Model for Cancer Development
- (2008) T. D. Halazonetis et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started